Canada markets open in 7 hours 42 minutes
  • S&P/TSX

    20,164.96
    -23.47 (-0.12%)
     
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • DOW

    35,144.31
    +82.76 (+0.24%)
     
  • CAD/USD

    0.7965
    -0.0007 (-0.08%)
     
  • CRUDE OIL

    72.10
    +0.19 (+0.26%)
     
  • BTC-CAD

    46,511.57
    -2,133.68 (-4.39%)
     
  • CMC Crypto 200

    877.58
    -37.91 (-4.14%)
     
  • GOLD FUTURES

    1,796.00
    -3.20 (-0.18%)
     
  • RUSSELL 2000

    2,216.92
    +7.27 (+0.33%)
     
  • 10-Yr Bond

    1.2760
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,094.50
    -23.25 (-0.15%)
     
  • VOLATILITY

    17.58
    +0.38 (+2.21%)
     
  • FTSE

    7,025.43
    -2.15 (-0.03%)
     
  • NIKKEI 225

    27,978.68
    +145.39 (+0.52%)
     
  • CAD/EUR

    0.6748
    -0.0002 (-0.03%)
     

Here's Why I Think Extendicare (TSE:EXE) Is An Interesting Stock

·3 min read

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.'

So if you're like me, you might be more interested in profitable, growing companies, like Extendicare (TSE:EXE). Even if the shares are fully valued today, most capitalists would recognize its profits as the demonstration of steady value generation. While a well funded company may sustain losses for years, unless its owners have an endless appetite for subsidizing the customer, it will need to generate a profit eventually, or else breathe its last breath.

See our latest analysis for Extendicare

How Fast Is Extendicare Growing?

If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS). Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, Extendicare has grown EPS by 17% per year, compound, in the last three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be smiling.

I like to see top-line growth as an indication that growth is sustainable, and I look for a high earnings before interest and taxation (EBIT) margin to point to a competitive moat (though some companies with low margins also have moats). The good news is that Extendicare is growing revenues, and EBIT margins improved by 6.3 percentage points to 11%, over the last year. Ticking those two boxes is a good sign of growth, in my book.

You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.

earnings-and-revenue-history
earnings-and-revenue-history

In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of Extendicare's forecast profits?

Are Extendicare Insiders Aligned With All Shareholders?

Like the kids in the streets standing up for their beliefs, insider share purchases give me reason to believe in a brighter future. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. However, insiders are sometimes wrong, and we don't know the exact thinking behind their acquisitions.

It's good to see Extendicare insiders walking the walk, by spending CA$362k on shares in just twelve months. When you contrast that with the complete lack of sales, it's easy for shareholders to brim with joyful expectancy. Zooming in, we can see that the biggest insider purchase was by Vice President Ali Mir for CA$100k worth of shares, at about CA$5.31 per share.

Should You Add Extendicare To Your Watchlist?

For growth investors like me, Extendicare's raw rate of earnings growth is a beacon in the night. Not only is that growth rate rather juicy, but the insider buying makes my mouth water. To put it succinctly; Extendicare is a strong candidate for your watchlist. It's still necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Extendicare (at least 2 which are significant) , and understanding them should be part of your investment process.

There are plenty of other companies that have insiders buying up shares. So if you like the sound of Extendicare, you'll probably love this free list of growing companies that insiders are buying.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting